DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents
Authors
Keywords
-
Journal
MOLECULES
Volume 21, Issue 12, Pages 1741
Publisher
MDPI AG
Online
2016-12-23
DOI
10.3390/molecules21121741
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trastuzumab in the Treatment of Breast Cancer
- (2016) Sofia Maximiano et al. BIODRUGS
- Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance
- (2016) Rachelle L. Dillon et al. JOURNAL OF IMMUNOTHERAPY
- Mechanisms of Resistance to Antibody–Drug Conjugates
- (2016) Frank Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Antibody-drug conjugates: Current status and future perspectives
- (2016) Rémy Gébleux et al. PHARMACOLOGY & THERAPEUTICS
- Apoptosis and necroptosis induced by stenodactylin in neuroblastoma cells can be completely prevented through caspase inhibition plus catalase or necrostatin-1
- (2016) Letizia Polito et al. PHYTOMEDICINE
- Biological activities of ribosome-inactivating proteins and their possible applications as antimicrobial, anticancer, and anti-pest agents and in neuroscience research
- (2015) Ouafae Akkouh et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Immunoconjugates in the management of hairy cell leukemia
- (2015) Robert J. Kreitman et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Potential therapeutic applications of plant toxin-ricin in cancer: challenges and advances
- (2015) Nikhil Tyagi et al. TUMOR BIOLOGY
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen
- (2014) Raffit Hassan et al. CANCER
- Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
- (2014) Roger Gilabert-Oriol et al. CURRENT PHARMACEUTICAL DESIGN
- Ribosome-inactivating proteins: From toxins to useful proteins
- (2013) Fiorenzo Stirpe TOXICON
- Ribosome-inactivating proteins
- (2013) Matthew J Walsh et al. Virulence
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- Differential inhibitory potencies and mechanisms of the type I ribosome inactivating protein marmorin on estrogen receptor (ER)-positive and ER-negative breast cancer cells
- (2012) Wen Liang Pan et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- A Detailed Mammosphere Assay Protocol for the Quantification of Breast Stem Cell Activity
- (2012) Frances L. Shaw et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin
- (2012) Mark Kowalski et al. JOURNAL OF UROLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
- (2012) Levi A. Garraway et al. Cancer Discovery
- The cancer stem cell: premises, promises and challenges
- (2011) Hans Clevers NATURE MEDICINE
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin
- (2009) Jeannick Cizeau et al. JOURNAL OF IMMUNOTHERAPY
- Antibody-Drug Conjugates for Cancer Therapy
- (2008) Paul J. Carter et al. CANCER JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started